Microfluidic apoptosis chip for drug screening to improve and personalize cancer therapy
2008 (English)In: 12th International Conference on Miniaturized Systems for Chemistry and Life Sciences - The Proceedings of MicroTAS 2008 Conference, Chemical and Biological Microsystems Society , 2008, 549-551 p.Conference paper (Refereed)
Currently, the knowledge on breast cancer treatment is increasing, however, there are still hardly any assays present to match patients to the right form of therapy to enhance the therapeutic effectiveness. Therefore a microfluidic device is developed to analyze the hormonal and chemosensitivity of first breast cancer cell lines (MCF-7) and in a later stage a patients' own tumor cells. The apoptotic inducers tumor necrosis factor-α, in combination with cycloheximide, and staurosporine stained MCF-7 cells positive for Annexin V and PI, and showed a decrease in area coverage as compared to untreated cells.
Place, publisher, year, edition, pages
Chemical and Biological Microsystems Society , 2008. 549-551 p.
Apoptosis, Cancer therapy, Drug screening, Lab-on-a-chip, Personalized medicine
IdentifiersURN: urn:nbn:se:kth:diva-164353ScopusID: 2-s2.0-84902503974OAI: oai:DiVA.org:kth-164353DiVA: diva2:805825
12th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2008, 12 October 2008 through 16 October 2008, San Diego, CA, United States
QC 201504162015-04-162015-04-162015-04-16Bibliographically approved